相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML
Cihangir Duy et al.
CANCER DISCOVERY (2019)
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation
Jia Yi Fong et al.
CANCER CELL (2019)
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients
Gerwin Huls et al.
BLOOD (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Epigenetic therapy in immune-oncology
Peter A. Jones et al.
NATURE REVIEWS CANCER (2019)
PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery
Shanshan Gu et al.
BIOESSAYS (2018)
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein et al.
BLOOD (2018)
A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia
Yali Xu et al.
CANCER CELL (2018)
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
Tamara Maes et al.
CANCER CELL (2018)
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Wanqiang Sheng et al.
CELL (2018)
Multiplexed Proteome Dynamics Profiling Reveals Mechanisms Controlling Protein Homeostasis
Mikhail M. Savitski et al.
CELL (2018)
Visualizing transcription factor dynamics in living cells
Zhe Liu et al.
JOURNAL OF CELL BIOLOGY (2018)
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes
Naval Daver et al.
LEUKEMIA (2018)
Targeted Enhancer Activation by a Subunit of the Integrator Complex
Elisa Barbieri et al.
MOLECULAR CELL (2018)
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Lynn Quek et al.
NATURE MEDICINE (2018)
Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses
Israel Canadas et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Imaging dynamic and selective low-complexity domain interactions that control gene transcription
Shasha Chong et al.
SCIENCE (2018)
Peptidomimetic blockade of MYB in acute myeloid leukemia
Kavitha Ramaswamy et al.
NATURE COMMUNICATIONS (2018)
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
Andrew M. Intlekofer et al.
NATURE (2018)
Functional genomic landscape of acute myeloid leukaemia
Jeffrey W. Tyner et al.
NATURE (2018)
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
James J. Harding et al.
CANCER DISCOVERY (2018)
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
C. Dafflon et al.
LEUKEMIA (2017)
Pharmacological inhibition of the transcription factor PU.1 in leukemia
Ileana Antony-Debre et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Epigenetics and immunotherapy: The current state of play
Jennifer Dunn et al.
MOLECULAR IMMUNOLOGY (2017)
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
Tyler E. Miller et al.
NATURE (2017)
The cancer epigenome: Concepts, challenges, and therapeutic opportunities
Mark A. Dawson
SCIENCE (2017)
Click chemistry enables preclinical evaluation of targeted epigenetic therapies
Dean S. Tyler et al.
SCIENCE (2017)
Impact of cytosine methylation on DNA binding specificities of human transcription factors
Yimeng Yin et al.
SCIENCE (2017)
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia
Alan H. Shih et al.
CANCER DISCOVERY (2017)
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
Jacob L. Glass et al.
CANCER DISCOVERY (2017)
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
Simon J. Hogg et al.
CELL REPORTS (2017)
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Michael D. Amatangelo et al.
BLOOD (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening
E. Robert McDonald et al.
CELL (2017)
Defining a Cancer Dependency Map
Aviad Tsherniak et al.
CELL (2017)
The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation
S. S. Tarighat et al.
LEUKEMIA (2016)
Insulator dysfunction and oncogene activation in IDH mutant gliomas
William A. Flavahan et al.
NATURE (2016)
Ever-Changing Landscapes: Transcriptional Enhancers in Development and Evolution
Hannah K. Long et al.
CELL (2016)
CTCF: making the right connections
Rodolfo Ghirlando et al.
GENES & DEVELOPMENT (2016)
Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia
Helena Boutzen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Functional interdependence of BRD4 and DOT1L in MLL leukemia
Omer Gilan et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Functional interdependence of BRD4 and DOT1L in MLL leukemia
Omer Gilan et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2016)
Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study
Celine Berthon et al.
LANCET HAEMATOLOGY (2016)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
David Roulois et al.
CELL (2015)
Disruptions of Topological Chromatin Domains Cause Pathogenic Rewiring of Gene-Enhancer Interactions
Dario G. Lupianez et al.
CELL (2015)
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Katherine B. Chiappinelli et al.
CELL (2015)
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Jing Lu et al.
CHEMISTRY & BIOLOGY (2015)
Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300
Sagar Uttarkar et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Catalytic in vivo protein knockdown by small-molecule PROTACs
Daniel P. Bondeson et al.
NATURE CHEMICAL BIOLOGY (2015)
Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter et al.
SCIENCE (2015)
Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
Andreas D. Orskov et al.
ONCOTARGET (2015)
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition
Andrew Kernytsky et al.
BLOOD (2015)
Results of Phase 2 Randomized Study of Low-Dose Decitabine With or Without Valproic Acid in Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia
Jean-Pierre Issa et al.
CANCER (2015)
Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes
Diwakar R. Pattabiraman et al.
BLOOD (2014)
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
Rafael Bejar et al.
BLOOD (2014)
A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome
Mark Kirschbaum et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active Tetramers
David A. Russler-Germain et al.
CANCER CELL (2014)
Looping Back to Leap Forward: Transcription Enters a New Era
Michael Levine et al.
CELL (2014)
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
Thomas Prebet et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
Courtney D. DiNardo et al.
LEUKEMIA & LYMPHOMA (2014)
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Jan Kroenke et al.
SCIENCE (2014)
TFIID subunit TAF4 directs promoter occupancy of nuclear receptor HNF4A during post-natal hepatocyte differentiation
Daniil Alpern et al.
ELIFE (2014)
An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors
Alison C. West et al.
CANCER RESEARCH (2013)
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
E. H. Estey
LEUKEMIA (2013)
DNA-Binding Small Molecules as Inhibitors of Transcription Factors
Chung-Hang Leung et al.
MEDICINAL RESEARCH REVIEWS (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Rob A. Cairns et al.
CANCER DISCOVERY (2013)
The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
William J. Harris et al.
CANCER CELL (2012)
In Epigenetic Therapy, Less Is More
Hui Shen et al.
CELL STEM CELL (2012)
Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia
Tino Schenk et al.
NATURE MEDICINE (2012)
Transcription factors: from enhancer binding to developmental control
Francois Spitz et al.
NATURE REVIEWS GENETICS (2012)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Jay P. Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Intra-tumour heterogeneity: a looking glass for cancer?
Andriy Marusyk et al.
NATURE REVIEWS CANCER (2012)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt et al.
CANCER CELL (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Quantitative DNA methylation predicts survival in adult acute myeloid leukemia
Lars Bullinger et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Maria E. Figueroa et al.
CANCER CELL (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells
Maika Almstedt et al.
LEUKEMIA RESEARCH (2010)
Selective inhibition of BET bromodomains
Panagis Filippakopoulos et al.
NATURE (2010)
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Paul W. Hollenbach et al.
PLOS ONE (2010)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Lenny Dang et al.
NATURE (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
An essential switch in subunit composition of a chromatin remodeling complex during neural development
Julie Lessard et al.
NEURON (2007)
Baf60c is essential for function of BAF chromatin remodelling complexes in heart development
H Lickert et al.
NATURE (2004)
5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation:: mechanistic studies and their implications for cancer therapy
JK Christman
ONCOGENE (2002)
分享论文
